{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T05:10:05Z","timestamp":1751087405114,"version":"3.41.0"},"reference-count":18,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2025]]},"DOI":"10.3960\/jslrt.25001","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T22:07:11Z","timestamp":1748556431000},"page":"121-128","source":"Crossref","is-referenced-by-count":0,"title":["Successful treatment of smoldering multiple myeloma-associated type I cryoglobulinemia with bortezomib and autologous peripheral blood stem cell transplantation"],"prefix":"10.3960","volume":"65","author":[{"given":"Daiki","family":"Hirano","sequence":"first","affiliation":[{"name":"Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroatsu","family":"Iida","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akari","family":"Iwakoshi","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiyo","family":"Sunohara","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Holy Spirit Hospital, Nagoya, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michita","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, National Hospital Organization Nagoya Medical Center, Nagoya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiko","family":"Imahashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Adachi","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Nagai","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 N\u00e9el A, Perrin F, Decaux O <i>et al.<\/i> Long-term outcome of monoclonal (type 1) cryoglobulinemia. Am J Hematol. 2014; 89: 156-161.","DOI":"10.1002\/ajh.23608"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Terrier B, Karras A, Kahn JE <i>et al.<\/i> The spectrum of type I cryoglobulinemia vasculitis: new insights based on 64 cases. Medicine (Baltimore). 2013; 92: 61-68.","DOI":"10.1097\/MD.0b013e318288925c"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Harel S, Mohr M, Jahn I <i>et al.<\/i> Clinico-biological characteristics and treatment of type I monoclonal cryoglobulinaemia: a study of 64 cases. Br J Haematol. 2015; 168: 671-678.","DOI":"10.1111\/bjh.13196"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Sidana S, Rajkumar SV, Dispenzieri A <i>et al.<\/i> Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. Am J Hematol. 2017; 92: 668-673.","DOI":"10.1002\/ajh.24745"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Muchtar E, Magen H, Gertz MA. How I treat cryoglobulinemia. Blood. 2017; 129: 289-298.","DOI":"10.1182\/blood-2016-09-719773"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Rajkumar SV, Dimopoulos MA, Palumbo A <i>et al.<\/i> International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15: e538-e548.","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Durie BG, Harousseau JL, Miguel JS <i>et al.<\/i> International uniform response criteria for multiple myeloma. Leukemia. 2006; 20: 1467-1473.","DOI":"10.1038\/sj.leu.2404284"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Rajkumar SV, Harousseau JL, Durie B <i>et al.<\/i> Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011; 117: 4691-4695.","DOI":"10.1182\/blood-2010-10-299487"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Ghembaza A, Boleto G, Bommelaer M <i>et al.<\/i> Prognosis and long-term outcomes in type I cryoglobulinemia: A multicenter study of 168 patients. Am J Hematol. 2023; 98: 1080-1086.","DOI":"10.1002\/ajh.26944"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Payet J, Livartowski J, Kavian N <i>et al.<\/i> Type I cryoglobulinemia in multiple myeloma, a rare entity: analysis of clinical and biological characteristics of seven cases and review of the literature. Leuk Lymphoma. 2013; 54: 767-777.","DOI":"10.3109\/10428194.2012.671481"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Besada E, Vik A, Koldingsnes W, Nossent JC. Successful treatment with bortezomib in type-1 cryoglobulinemic vasculitis patient after rituximab failure: a case report and literature review. Int J Hematol. 2013; 97: 800-803.","DOI":"10.1007\/s12185-013-1323-y"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Ramirez GA, Campochiaro C, Salmaggi C <i>et al.<\/i> Bortezomib in type I cryoglobulinemic vasculitis: are we acting too late? Intern Med. 2015; 54: 1119-1123.","DOI":"10.2169\/internalmedicine.54.3668"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Spizzo G, Mitterer M, Gunsilius E. Bortezomib for the treatment of refractory Type-1 cryoglobulinaemia. Br J Haematol. 2010; 150: 235-237.","DOI":"10.1111\/j.1365-2141.2010.08184.x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Runge JS, Pearson TL, Keren DF <i>et al.<\/i> Multiple myeloma presenting as cryoglobulinemic vasculitis. JAAD Case Rep. 2021; 11: 81-83.","DOI":"10.1016\/j.jdcr.2021.03.026"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Harousseau JL, Attal M, Avet-Loiseau H <i>et al.<\/i> Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol. 2010; 28: 4621-4629.","DOI":"10.1200\/JCO.2009.27.9158"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Petersen T, Riviere S, Malbos S <i>et al.<\/i> Subclasses of Monoclonal (Type I) Immunoglobulin G Cryoglobulins: Report on Two Distinct Cases with Myeloma. Clin Lab. 2018; 64: 615-618.","DOI":"10.7754\/Clin.Lab.2017.171043"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Mateos MV, Mart\u00ednez-L\u00f3pez J, Rodriguez Otero P <i>et al.<\/i> Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance. J Clin Oncol. 2024; 42: 3247-3256.","DOI":"10.1200\/JCO.23.02771"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Kyle RA, Remstein ED, Therneau TM <i>et al.<\/i> Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007; 356: 2582-2590.","DOI":"10.1056\/NEJMoa070389"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/2\/65_25001\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T04:45:28Z","timestamp":1751085928000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/2\/65_25001\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.25001","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"type":"print","value":"1346-4280"},{"type":"electronic","value":"1880-9952"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"25001"}}